European Companies Search Engine
EU funding (€2,717,755): Preventing Therapy Resistance in Esophageal Cancer Using Advanced Models and Molecular Signatures Hor11 Jul 2023 EU Research and Innovation programme "Horizon"
Overview
Text
Preventing Therapy Resistance in Esophageal Cancer Using Advanced Models and Molecular Signatures
In 2035, cancer will have become the leading cause of death in the EU. In line with the Horizon Europe Plan to Beat Cancer, one of the five Horizon Missions, the PRESSURE network sets out to train 10 future experts who will push the development and clinical implementation of effective treatments and policies against therapy resistance in cancer. This innovative project will specifically focus on esophageal adenocarcinoma as one of the most complex cancer types in terms of resistance, and most urgently in need of novel solutions. Prominent factors that contribute to the poor outcome of esophageal cancer are a high degree of acquired resistance, and heterogeneous responses to the available therapies. Despite this knowledge, there are currently no consensus treatments for this disease in the EU, and there is insufficient awareness of the need for a unified low-risk treatment strategy. Numerous different regimens are currently given across the continent, and as a result highly divergent outcomes of EAC are observed. This adds to Cancer Inequalities in Europe. To address this, PRESSURE researchers will receive exhaustive intersectoral training, and deliver high-quality knowledge, across the entire value chain: Epidemiology, imaging, patient-derived model systems, resistance mechanisms, diagnostics, patient-centricity, valorization, and treatment. By receiving this diverse training, the ESRs will become next generation thinkers and problem-solvers, and will be able to deliver creative contributions to all fields involved in the combatting of cancer with unique solutions applicable in the clinic and society. This combination of complementary research expertise and rich training is not currently offered in an EU network.
Funded Companies:
| Company name | Funding amount |
| AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN | ? |
| Institut National de la Sante et de la Recherche Medicale | €282,694 |
| Karolinska Institutet | €293,710 |
| Masarykuv Onkologicky Ustav | €237,038 |
| Nordic Bioscience A/S | €301,788 |
| React4Life S.p.A. | €259,438 |
| STICHTING AMSTERDAM UMC | €823,111 |
| Universita Degli Studi Di Palermo | €259,438 |
| UNIVERSITAET LEIPZIG | €260,539 |
Source: https://cordis.europa.eu/project/id/101119464
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: agentschap College ter Beoordeling van Geneesmiddelen, Utrecht, Netherlands.
The visualizations for "AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN - EU funding (€2,717,755): Preventing Therapy Resistance in Esophageal Cancer Using Advanced Models and Molecular Signatures"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
